Corina E. Dutcus
Eisai (United States) · 164 works · 18,649 citations · h-index 42
Top works
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
- Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
- Lenvatinib for Anaplastic Thyroid Cancer
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
- Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes
- A Phase II Study of the Safety and Efficacy of Lenvatinib in Patients with Advanced Thyroid Cancer
- A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma
- Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
- Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer